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Abstract
Allogeneic stem cell transplantation (ASCT) from related or unrelated donors may cure patients with myelodysplastic
syndromes (MDS), a heterogeneous group of clonal stem cell disorders. We analysed 384 elderly patients (55-69
years) with advanced MDS who received either ASCT (n=247) and were reported to The European Group for Blood
and Marrow Transplantation (EBMT) or a non –transplant approach (n=137) reported to the Düsseldorf registry.
Besides an attempt to answer the question of „comparison“, the purpose of this work is to explain the difficulties in
comparing a non-transplant with a transplant cohort, when death before transplant is likely but unknown and the
selection of patients for transplant is based on assumptions. It shows which methods are almost always biased and
that even the most sophisticated approaches crucially rely on clinical assumptions. Using the most appropriate model
for our data, we derive an overall univariate non-significant survival disadvantage for the transplant cohort (HR: 1.29,
p = 0.11). We show that such an “average” hazard ratio is however misleading due to non-proportionality of the
hazards reflecting early treatment related mortality, the occurring of which is logically correlated with the interval
between diagnosis and transplant creating a disproportional drop in the (reconstructed) survival curve of the
transplanted patients. Also in multivariate analysis (correcting for age > 60 (HR: 1.4, p = 0.02) and abnormal
cytogenetics (HR: 1.46, p = 0.01)), transplantation seems to be worse (HR: 1.39, p = 0.05) but only in the (incorrect
but commonly applied) model without time varying covariates. The long term (time depending) hazard ratio is shown
to be virtually 1 and overall survival is virtually identical in both groups. Nonetheless no conclusion can be reached
from a clinical point of view without assumptions which are by their very nature untestable unless all patients would
be followed from diagnosis.
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Introduction
Myelodysplastic syndromes (MDS) constitute a
heterogeneous group of clonal stem cell disorders
characterized by hypercellular bone marrow, cytopenias and
dysplastic cell features. Allogeneic stem cell transplantation
from related or unrelated donors may cure patients with
myelodysplastic syndromes [1–3]. However, due to the high
treatment-related morbidity and mortality, this treatment
approach is mainly performed in young patients with good
performance status. Apart from the basic question whether a
transplant should be performed at all, the optimal timing of
transplantation is of great clinical interest but difficult to assess.
Due to the lack of randomised trials, a retrospective
comparison between transplanted patients and non-
transplanted patients has to be performed. In order to avoid the
inherent biases in non-randomized data as much as possible,
investigators used a multi-state model. In this model, allogeneic
stem cell transplantation maximized overall survival if stem cell
transplantation is performed immediately after diagnosis for
patients with IPSS intermediate 2 and high risk, while for
patients with IPSS intermediate 1 and low risk delayed
transplantation had maximal life expectancy [4].
Since MDS is a disease of elderly patients with a median age
of more than 70 years at diagnosis, the majority of patients
have been excluded from allogeneic stem cell transplantation
option until recently. The reduction of therapy-related
complications and the introduction of reduced-intensity
conditioning regimens has increased the upper age limit and
encouraging results of allogeneic stem cell transplantation in
MDS-patients up to the age of 70 years have been reported
[5–11]. However, whether elderly patients with MDS should
undergo allogeneic stem cell transplantation is a matter of
debate. We analysed, using a multi-state model with left and
right truncation as well as time varying covariates, outcome of
elderly advanced MDS patients (aged 55-69 years) with RAEB
or RAEB-t who received either only best supportive care and
were reported to the Düsseldorf registry (n = 137) or who
received allogeneic stem cell transplantation and were reported
to The European Group for Blood and Marrow Transplantation
(EBMT) (n = 247).
Design and Methods
This study aims at a comparison of two treatment modalities,
one of which is transplantation, by analysing data from two
separately obtained cohorts of patients. One cohort originates
from a transplantation registry which only contains data from
patients actually having received a transplant; the other cohort
originates from a regional registry of patients not undergoing
transplant. This study has a four-fold purpose [1]: to show that
traditional statistical analysis approaches are inappropriate and
biased [2]; to show that more advanced methods like multi-
state models can aid in avoiding part of the bias inherent to an
observational comparison [3]; to obtain an optimal estimate of
the treatment effect from this data set to support the continuing
clinical discussion on this topic; and [4] to show that even such
an optimal estimate relies on implicit (clinical) assumptions that
cannot be verified.
After having obtained optimal inference from this data set,
some uncertainties still remain as to the amount of residual
bias. This implies that differences between the two treatment
modalities, in terms of overall survival from diagnosis, cannot
be presented as sufficient evidence.
The analysis of the actual data has been performed in a
multi-state model. A multi-state model defines a number of
states, based on clinically relevant stages in the disease/
recovery process of the patient. Interest is in the rates of
transitions between these states and how covariates influence
these rates. For more details see 12. The multi-state model
appropriate for our analysis is shown in Figure 1.
From the data the transition rates from states Diagnosis to
Death can be estimated in the non-transplanted cohort with
complete data from diagnosis onwards. The transition rate from
Diagnosis to Transplant cannot be estimated directly since the
transplant cohort does not contain patients who die while
waiting for transplant (hence patients who would go into
transition if they would have survived). The transition rate from
Transplant to Death can be estimated by standard methods,
provided left truncation is taken into account. The
corresponding survival curve does estimate survival after
transplant, but the curve is actually equivalent to a
counterfactual survival curve in a cohort where each individual
is immediately transplanted, a fact easily overlooked. Such a
survival curve does not correspond to survival observed in any
real-life cohort, where patients are not immediately
transplanted and where as a result patients can also die before
transplant.
If and only if one is willing to assume that at diagnosis
patients with an intention-to-treat for transplant are on average
identical to patients not elected to be transplanted, the death
rate as a function of time elapsed since diagnosis can be
estimated from the non-transplanted cohort. By applying this
probability of dying before transplant to the transplanted cohort,
one can reconstruct survival in the transplant cohort.
In the Appendix S1, by using simulation data, the naïve
approach (i.e. direct comparison instead of multi state models)
is shown to yield a severe bias in estimating survival from
diagnosis. This affects both the comparison of standard
Kaplan-Meier or Cox survival curves in the two cohorts, even
Figure 1.  Multi-state model comparing transplant vs.
non-transplant approach in elderly (55-69y) MDS patients.  
doi: 10.1371/journal.pone.0074368.g001
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while using left truncation to account for the unobserved period
between diagnosis and transplant in the transplant cohort. The
notion of left truncation is also referred to in the literature as
“zero time shift bias” or “lead time bias” or “immortality time
bias”.
More technical details on statistical and computational issues
are also outlined in the Appendix S1. All computations related
to the multi-state modelling approach were done using the
mstate package [13] version 0.2.1 in R version 2.9.1.
Data Sources
All outcome data were obtained from prospectively collected
databases.
Non-transplant cohort
Data from non-transplanted MDS patients with RAEB or
RAEB-t were derived from the Düsseldorf registry. Only
patients aged 55-69 years at diagnosis were selected. Patients
who received transplantation were excluded. 137 patients were
eligible for the analysis. Supportive care consisted of blood
transfusions, growth factors, low dose cytosine arabinoside or
in some cases intensive chemotherapy without transplantation.
Diagnosis was RAEB in 100 and RAEB-t in 37 patients and the
date of diagnosis was known in all cases (see table 1). The
Düsseldorf registry is an MDS registry from a region in West-
Germany which includes about 5 million inhabitants, data on
morphology, treatment and death were reported on an annual
basis.
Transplant cohort
The transplanted patients were obtained from the EBMT
database. 247 patients (male: n = 169, female: n = 78) were
eligible for analysis. Disease status at diagnosis was RAEB (n
= 173) and RAEB-t (n = 74). At time of transplantation
diagnosis was RAEB (n = 135), RAEB-t (n = 83) and
transformed secondary acute leukemia (n = 29). One- hundred-
thirty five patients received induction chemotherapy and 75
achieved CR, while 1 achieved only PR and 20 relapsed or
progressed after initial response and 37 patients were primary
refractory and in 2 patients response status was not given, so
overall at time of transplantation 75 patients were in CR, 149 in
non-CR and in 23 patients information about pre-treatment
were missing. All patients gave written informed consent for
this study. The transplant cohort gave consent to The
European Group for Blood and Marrow Transplantation
(EBMT) for using their data for scientific purposes. As a
Working Party of the EBMT (CLWP), we were allowed to use
the data for this study. The non-transplant cohort gave consent
to Ulrich Germing (coauthor) for using their data for scientific
purposes. All data were analyzed anonymously. For details see
table 1.
Results
Basic description
The median follow-up among survivors in the non-transplant
cohort was 11 months with a maximum follow-up of 95 months.
Median follow-up among survivors of the transplant cohort
measured from diagnosis was 56 months (with a maximum of
132 months), while measured from transplant it was 42 months
(with a maximum of 109 months). Median time between date of
diagnosis and date of transplant observed in the transplant
cohort was 7 months (survivors and deaths together). The
Table 1.
 EBMT Düsseldorf-Registry
 (n = 247) (n = 137)
 at diagnosis at diagnosis
RAEB 173 (70%) 100 (73%)
RAEB-t 74 (30%) 37 (27%)
 at transplant  
RAEB 135 (54%)  
RAEB-t 83 (34%)  
transformed to sAML 29 (12%)  
Intensive
chemotherapy before
transplantation
  
yes n=135  
no n = 89  
unknown n = 23  
Status at
transplantation   
CR n = 75  
non CR n=149  
missing n = 23  
Patients sex   
male 169 (68%) 83 (61%)
female 78 (32%) 54 (39%)
Conditioning   
standard 77 (31%)  
reduced 170 (69%)  
Median age at
diagnosis 58 years 62 years
55-60 167 (67%) 51 (37%)
60-69 80 (33%) 86 (63%)
Cytogenetics known n = 88 n = 79
normal 35 (40%) 40 (51%)
abnormal 53 (60%) 39 (49%)
Percentiles of time
from diagnosis to
transplant in days
1st 35 99th 10586  
 5th 73 95th 1395  
 10th 97 90th 1191  
 25th 141 75th 475  
 median 226    
Time period diagnosis 1971-2004 1998-2005
Time period
transplant 1998-2004 (50% in 2003 + 2004)  
Donor   
HLA identical n = 176 (71%)  
matched unrelated n = 71 (29%)  
doi: 10.1371/journal.pone.0074368.t001
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cumulative incidence of non-relapse mortality of the transplant
cohort at 1 year and 3 years post-transplant was 15% and
31%, respectively. The cumulative incidence of relapse was
14% and 29% at the same time points. The 5 year estimated
overall survival from diagnosis was 23% (95% CI: 12-34) for
the non-transplant cohort; 5 year estimated overall survival
from transplant was 31% (95% CI 25-38) for the transplant
cohort.
The interested reader is referred to the Appendix S1 where
we show that a number of naïve (and commonly applied)
methods will estimate the wrong parameters and would
possibly yield a (highly) biased interpretation of the data and
that the multi-state approach allows in principle for a correct
interpretation.
From the Appendix S1 we may infer that a multi-state
approach will yield an unbiased estimate of the treatment effect
(i.e. transplant versus non-transplant) if the death rate in both
populations is the same before the transplant (as assumed by
the so-called Markov model).
In our study, we can only assume that the rates are the
same. This in turn is only true if indeed the decision to go for
transplant is not correlated with any patient characteristic which
itself is correlated with the probability of mortality. In a
randomized study this would be guaranteed by the
randomization procedure; in our study it can only be
approximated by correction for status/stage related factors at
diagnosis, age of the patient etc. and knowledge about the
reasons for (not) attempting a transplant as a treatment
modality.
Comparison of treatment modalities
Applying the multi-state method, the overall (average) hazard
ratio of the transplant group versus best supportive care,
assuming proportional hazards, is estimated as 1.29 (95% CI:
0.95-1.76; p = 0.11). After adjustment for year of diagnosis as a
continuous variable, the hazard ratio is the same 1.28 (95% CI:
0.94-1.74; p = 0.12). There was no evidence that the effect of
year of diagnosis differed between Düsseldorf registry and
EBMT database (p = 0.79) The median overall survival from
diagnosis for the non-transplant and the transplant cohort was
virtually identical: 19 months, (see Figure 2).
From Figure 2 we may infer that both populations, given the
(unknown) selection mechanisms underlying the selection of
patients for (non-)transplant, both groups have the same
survival. Note that the usual steep descend of the curve among
transplanted patient directly after transplant due to TRM is
entirely invisible since the curves start at diagnosis and all
transplanted patients start their period where they are at risk for
TRM, at a different point in time (spreading this usually steep
descent over a long period “after diagnosis” compared to a
relatively short period “after transplant”) which makes this
pattern almost invisible.
In a multivariate analysis and assuming proportional hazards
(which turns out to be an incorrect assumption as discussed
below), adjusting for age at diagnosis, sub-diagnosis (RAEB
vs. RAEB-t), cytogenetics (abnormal vs. normal), the hazard
ratio for transplantation was HR: 1.37 (95% CI: 1.00-1.89; p =
0.05); for age > 60: HR 1.43 (95% CI: 1.07-1.91; p = 0.02), for
RAEB-t: HR 1.03 (95% CI: 0.78-1.37; p = 0.84), and for
abnormal cytogenetics: HR 1.35 (95% CI: 1.00-1.81; p = 0.05)
Corresponding to this multivariate analysis belongs a graph
estimating the transition rates to death in both groups as well
as the transition rate from diagnosis to transplant (see Figure
3).
Horizontally the time axis measures time in years. The
vertical axis depicts the accumulated average rate (up to a
certain point in time) at which patients’ transit from one state to
the other. The absolute height of the curve is of no importance
for our discussion. It is the shape that counts for the clinical
interpretation:
The highest curve (1) depicts the cumulative transplantation
rate (estimated under right truncation (using the method
proposed by[14]) since diagnosis as a function of the number
of years elapsed since diagnosis. The curve is approximately a
straight line indicating that transition to transplant is almost
uniformly happening over time.
Figure 2.  Estimated Kaplan-Meier survival curves for
transplant and non-transplant cohorts, derived from a
multi-state model.  
doi: 10.1371/journal.pone.0074368.g002
Figure 3.  Estimated cumulative transition rates derived
from a multi-state model (1: Diagnosis-Transplant; 2:
Diagnosis-Death if not transplanted; 3: Transplant-Death);
time in years.  
doi: 10.1371/journal.pone.0074368.g003
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The lowest curve (2) is the mortality hazard in the non-
transplant group, measured in years since diagnosis and (3)
the mortality rate in the transplanted group measured in years
since transplant. Both curves flatten towards the end of the
horizontal axis, indicating a tendency of the underlying survival
curve to become “horizontal”. Clearly the death rate in the
transplanted group is much higher very shortly after diagnosis,
but one should bear in mind that TRM is an inherent
phenomenon among transplanted patients shortly after
transplant and those patients transplanted shortly after
diagnosis therefore exhibit mortality also shortly after diagnosis
as a result of the procedure and not necessarily as a result of
the short interval between diagnosis and transplant as a clinical
underlying risk factor. This phenomenon leads to the overall
(and misleading) estimate of a detrimental effect of
transplantation as an average hazard ratio (1.29 univariately or
1.37 multivariately) when using a simple but inappropriate Cox
model.
However, because of Treatment Related Mortality and the
broad range of periods between diagnosis and transplant, the
hazard ratio is not constant at all but varies significantly over
time.
In other words: while the notion of transplant related mortality
measured since “transplant” occurs in a fairly narrow time
range, the same phenomenon becomes more dispersed over
time when calculated from diagnosis and thus could easily be
misinterpreted as a continuing excess risk among transplanted
patients when looking at survival curves starting at diagnosis.
The following picture shows an estimate of this hazard ratio
(on a log scale so the vertical zero corresponds to a hazard
ratio of 1). The horizontal axis measures time in years since
diagnosis (on a non-linear scale).
Here we see from Figure 4 that the entire detrimental effect
of transplant when estimated as one average over the entire
follow up time, is generated in the first year after diagnosis
while thereafter the Hazard Ratio is 1 (log(HR)=0). The null
hypothesis that the hazard ratio is constant over time is
rejected (p= 0.028; for the test description see 15).
Further detailed analysis leads to an estimated HR of 5.8
during the first 3 months after diagnosis and a HR of almost
exactly 1 after a year.
In our population with age above 55, the interval between
diagnosis and transplant turns out not to be a risk factor at all
(after transplant). Although in the entire transplanted population
in the EBMT registry, the interval is indeed an adverse risk
factor, this well-known phenomenon turns out to hold only for
the younger patients: a strong and significant interaction
between age at transplant and interval between diagnosis and
transplant is indeed present in The EBMT Registry (data not
shown) and actually totally removes the supposed effect of the
interval in older patients.
Discussion
In the current study we attempted to answer the clinically
relevant question whether elderly patients (55-69 years) with
advanced MDS (RAEB and RAEB-t) may benefit from
allogeneic stem cell transplantation in comparison to a non-
transplant approach. We therefore collected data from RAEB
and RAEB-t patients who were registered either in a non-
transplant registry (Düsseldorf-Registry) or in a transplant
registry (EBMT-registry). Despite including several statistical
methods such as multi-state models, left and right truncation,
not all potential biases can be excluded and the analysis is still
based on (untestable or even likely to be untrue) assumptions.
First, transplant patients are registered only at time of
transplantation, which means death before transplantation is
not possible; therefore the death rate before transplantation
has to be estimated from the non-transplanted patients in the
Düsseldorf registry and both the time from diagnosis to
transplant and from transplantation to death have to be
estimated taking into account right and left truncation
respectively.
Secondly, an untestable (and unlikely to be true) assumption
is that the transplant and non-transplant group are comparable
with respect to risk factors at diagnosis. Since IPSS scoring
was not possible for both groups due to the lack of cytogenetic
data, we included only patients with advanced RAEB and
RAEB-t MDS to create comparable groups. However, this does
not exclude unmeasured selection bias for the transplant
cohort, since from diagnosis to transplant (median 7.4 months)
16% progressed to secondary acute leukemia or RAEB-t.
An approach similar to ours using a Markov model with
piecewise constant transition rates has been used by the
CIBMTR comparing (mainly younger) patients with MDS who
received a HLA identical sibling transplantation after standard
myeloablative conditioning with a cohort of patients without
transplant (4). They found for low and intermediate risk patients
a delayed transplantation is advantageous, while for patients
with intermediate 2 and high risk according IPSS immediate
stem cell transplantation is associated with a maximal life
expectancy.
Obviously optimal timing of transplant depends on the
differences in death rates between the non-transplant and the
transplant cohort (the transplant effect) over time. In our data
Figure 4.  Estimated log(hazard ratio) comparing the
transplant to the non-transplant cohort in a multi-state
model using a time-varying factor for the treatment effect,
together with a 95% confidence interval; the time is in
years.  
doi: 10.1371/journal.pone.0074368.g004
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we found a transplant effect that on average was in favor of the
non-transplant cohort over the whole follow-up period.
However, this average is not only an average over follow-up
time but also an average over all possible intervals between
diagnosis and transplant in our data; moreover the effect is a
reflection of current transplant practice correlated with risk
factors observed at diagnosis but lacking among those dying
before transplant.
This all implies that the outcome of a scenario analysis as
was performed in Cutler et al. [4] evaluating the effect of
specific assumptions on the timing of the transplant procedure
after diagnosis can only be done by modelling the effect of the
interval both before and after the transplant as well as looking
at possibly non-constant hazard ratio of transplant with respect
to death. If the interval-effect (between diagnosis and
transplant) would in reality be non-existent for survival after
transplant, the result would be rather trivial: since in these
models the death rate after diagnosis but before transplant is
estimated from the non-transplanted cohort, evidently both
cohorts should have more similar outcome the longer this
waiting time is assumed to be, forcing the hazard ratio towards
1. A short waiting time applies the death rate after transplant
very quickly after diagnosis; a long waiting time assumes a
death pattern equal to nontransplanted patients for an
extended period of time since diagnosis.
One should note that “early after diagnosis” is identical to
“early after transplant” for those patients transplanted shortly
after diagnosis. Transplanting patients shortly after diagnosis
will inevitably “generate” mortality, not because an early
transplant is necessarily bad (it might even reduce mortality) as
such but simply because mortality will be associated with the
transplant procedure anyhow and the earlier transplant is
scheduled, the earlier mortality occurs when measured “since
diagnosis”.
Hence in our opinion still no conclusion about the causal
effect of the interval between diagnosis and transplant can be
drawn from observational data, no matter how sophisticated
these models are, if sufficient covariates at diagnosis for
patients dying between diagnosis and transplant are lacking.
Obviously the group of transplant patients contains patients
with different levels of risk, according to their CR-status but
also according to the administration of intensive chemotherapy
or their resistance against chemo. We stress the fact that there
is not sufficient information in the data to rule out an
appreciable selection bias which could invalidate the crucial
assumption of equal mortality risk in both groups.
More generally speaking we have serious doubts whether
such conclusions can be drawn from such observational data
at all. There seems to be an unavoidable bias in data which
lack information at diagnosis as well as information on death
rates in the pre-transplant period, caused also by the
correlation between the phenomenon of unavoidable TRM and
the fact that “early after transplant” is the same as “early after
diagnosis” for patients transplanted quickly after diagnosis.
Disentangling this correlation requires data which are not
present. We therefore express the opinion that this crucial
assumption of equal death rates plays an equally essential part
in the Cutler paper without being made entirely explicit ( [4],
page 548). Differences in approach between the Cutler paper
and ours are in essence small: we use non-parametric or semi-
parametric models, Cutler uses parametric ones; we
emphasize that you need to know the death pattern while
waiting for an intended transplant; we emphasize that
unverifiable assumptions are needed also in the Cutler
approach. We can see no reason why the approach in the
Cutler paper, just like in our approach, could lead to
conclusions about the effect of the interval between diagnosis
and transplant without the aforementioned basic, unverifiable
assumptions. This is not a matter of being right or wrong for
any of these approaches: they just rely on crucial assumptions.
Moreover, even with an optimal choice of statistical
methodology, no valid analysis can be done without the
availability of a comprehensive dataset including all variables
with solid prognostic significance (such as IPSS-R).
In our analysis, an early disadvantage for stem cell
transplantation was probably by the non-relapse mortality of
the transplant cohort which exceeded 30% at 3 years. The non-
relapse mortality has been reduced in the more recent years by
reducing risk of severe GvHD and lowering the therapy-related
toxicity of the conditioning regimen [5,6,8-11]. Furthermore, if
no HLA-identical sibling is available a careful donor selection
by high resolution HLA-matching lowers the risk of non-relapse
mortality [16]. More recently hypomethylating agents in MDS
patients have been shown to prolong transformation to AML
and survival in comparison to “best supportive care” and have
been approved for treatment of high risk MDS [17]. In our non-
transplant cohort none of the patients received
hypomethylating agents. A prospective trial comparing
hypomethylating agents with a reduced-intensity transplant
approach according to donor availability is needed and has
been recently started as EBMT labelled trial in The German
MDS Study Group (NCT 01404741).
Finally, we would like to put forward our conclusion with
respect to the clinical target we tried to achieve, based on the
arguments put forward in this paper:
In order to obtain a reliable and useful answer to the effect of
the transplant, including the timing relative to the time of
diagnosis, a randomized clinical trial is absolutely necessary.
Such a trial should have both a randomization structure that
allows for a useful clinical interpretation as to the decision and
timing of an “intention to go for transplant” and should
incorporate both patient and clinic based parameters.
Especially the timing of transplant should be captured in the
design of the trial, for example by stratification or by multiple
randomizations in time. Unlike many other situations in which
observational data, if carefully modelled, could reach evidence
levels almost comparable to clinical trials, this is clearly not
easy in the framework of transplantation, unless of course a
register of patients from diagnosis onwards would be available
with a sufficiently rich information infrastructure to capture all
covariates correlated with the decision to go for transplant. The
latter is clearly a Utopia.
In conclusion we will have to use clinical trials to define and
assert the position and timing of the transplant procedure
among other treatment options since even an assertion that
allogeneic SCT is at least equivalent to the best alternative
Allogeneic SCT v. Non-Transplant Approaches in MDS
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therapy in a specific subgroup of patients cannot be
substantiated, not even by the best statistical methods
available today.
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